Nivolumab in patients with metastatic DNA mismatch repair deficient/microsatellite instability–high colorectal cancer (CheckMate 142): results of an open-label, multicentre, phase 2 study
Explore this paper's citation graph
Summary
Nivolumab provided durable responses and disease control, as well as long-term survival in pre-treated patients with dMMR/MSI-H mCRC, and is a new treatment option for these patients.
- Type
- article
- Published
- 2017-07-19
- Cited by
- 2,435
- References
- 30
- Access
- Open access
- OpenAlex
- https://openalex.org/W2739132742
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:4234696
Keywords
Nivolumab, Medicine, Irinotecan, Microsatellite instability, Colorectal cancer
References
- Randomized trial of TAS-102 for refractory metastatic colorectal cancer.
- PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
- Interpreting the significance of changes in health-related quality-of-life scores.
- Immune response against frameshift-induced neopeptides in HNPCC patients and healthy HNPCC mutation carriers.
- The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints
- Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
- New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).
- Deficient mismatch repair system in patients with sporadic advanced colorectal cancer
- BRAF-V600E is not involved in the colorectal tumorigenesis of HNPCC in patients with functional MLH1 and MSH2 genes
- Impact of BRAF Mutation and Microsatellite Instability on the Pattern of Metastatic Spread and Prognosis in Metastatic Colorectal Cancer
- Frameshift-mutation-derived peptides as tumor-specific antigens in inherited and spontaneous colorectal cancer
- Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.
- Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.
- Multicenter retrospective analysis of metastatic colorectal cancer (CRC) with high-level microsatellite instability (MSI-H).
- Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial.
- Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO2, COIN and FOCUS studies
- The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology.
- BRAF Mutations in Colorectal Cancer: Clinical Relevance and Role in Targeted Therapy
- Genomic Correlates of Immune-Cell Infiltrates in Colorectal Carcinoma
- Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial.
Cited by
- Emerging treatment options for BRAF-mutant colorectal cancer
- Immunotherapy of Colon Cancer
- Targeting PD-L1 Protein: Translation, Modification and Transport.
- Immunotherapy and metastatic colorectal cancers with microsatellite instability or mismatch repair deficiency.
- Immunotherapy for non-small cell lung cancers: biomarkers for predicting responses and strategies to overcome resistance
- SEOM clinical guidelines for diagnosis and treatment of metastatic colorectal cancer (2018)
- PD-1/PD-L1 blockade in cervical cancer: current studies and perspectives
- Detection of ERBB2 (HER2) Gene Amplification Events in Cell-Free DNA and Response to Anti-HER2 Agents in a Large Asian Cancer Patient Cohort
- Upfront progression under pembrolizumab followed by a complete response after encorafenib and cetuximab treatment in BRAF V600E‐mutated and microsatellite unstable metastatic colorectal cancer patient: A case report
- Deficient mismatch repair/microsatellite unstable colorectal cancer: Diagnosis, prognosis and treatment.
- Opportunities on the horizon for the management of early colon cancer.
- Nonoperative Management of dMMR/MSI-H Colorectal Cancer following Neoadjuvant Immunotherapy: A Narrative Review
- Sustained Disease Control in Immune Checkpoint Blockade Responders with Microsatellite Instability-high Colorectal Cancer after Treatment Termination
- Results from a phase 2b, randomized, multicenter study of GVAX pancreas and CRS-207 compared to chemotherapy in adults with previously-treated metastatic pancreatic adenocarcinoma (ECLIPSE Study).
- Multidisciplinary Treatment of Colorectal Cancer: Staging – Treatment – Pathology – Palliation
- PD-1 inhibition in metastatic dMMR/MSI-H colorectal cancer.
- Microsatellite instability status predicts response to anti-PD-1/PD-L1 therapy regardless the histotype: A comment on recent advances.
- Immunvermittelte Nebenwirkungen unter Checkpointinhibitoren
- Zielgerichtete Next-Generation-Sequencing-basierte Panelsequenzierung in Kombination mit immunhistochemischen Standardanalysen
- The Heat-Stable Enterotoxin Receptor, Guanylyl Cyclase C, as a Pharmacological Target in Colorectal Cancer Immunotherapy: A Bench-to-Bedside Current Report
Related papers
- Oxaliplatin─Based Chemotherapy の腹膜播種を伴うStage IV 大腸癌に対する効果
- A Pooled Analysis of 3 Phase II Trials of Salvage Nivolumab/Ipilimumab After Nivolumab in Renal Cell Carcinoma
- Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer.
- Phase I study of weekly oxaliplatin plus irinotecan in previously treated patients with metastatic colorectal cancer.
- Hyperprogressive disease during nivolumab or irinotecan treatment in patients with advanced gastric cancer
- The Role of 5-Fluorouracil (5-FU) Reintroduction with Irinotecan or Oxaliplatin in Truly 5-FU-Refractory Advanced Colorectal Cancer Patients
- Increased response of oxaliplatin or irinotecan on in vitro chemosensitivity to 5-fluorouracil in patients with colorectal cancer
- The hyperprogressive disease during nivolumab treatment or irinotecan treatment in patients with advanced gastric cancer.
- Rare Nivolumab-associated Super Hyper Progressive Disease in Patients With Advanced Gastric Cancer
- Treatment of advanced and metastatic colorectal cancer with combined chemotherapy based on oxaliplatin,irinotecan and fluorouracil